This association holds up when comparing benign and tumor cells, as well as comparing within primary or metastatic tumor cohorts, and remains significant when cases are stratified by molecular alterations associated with FASN expression, such as ERG gene fusions. This evidence concerns the gene FASN and metastatic neoplasm.